Disruptive Technology Content Hub ARK’s Unique Strategies for Navigating Volatility in Innovation By Evan HarpNovember 4, 2021
Disruptive Technology Content Hub Innovation: How to Navigate Through Periods of Volatility With ARK Invest By Evan HarpNovember 3, 2021
Disruptive Technology Content Hub Google and Genomics? It’s a More Plausible Mix Than Meets the Eye By Tom LydonOctober 12, 2021
Disruptive Technology Content Hub Gilded Age of Genomics Just Getting Started By Tom LydonSeptember 27, 2021
Disruptive Technology Content Hub Google Getting Into Genomics? It Already Is By Tom LydonSeptember 8, 2021
Disruptive Technology Content Hub Early Cancer Detection: Major Opportunity for Genomics Investors By Tom LydonSeptember 3, 2021
Disruptive Technology Content Hub Genomics Could Again Be Prime Time Idea By Tom LydonAugust 25, 2021
Disruptive Technology Content Hub Genomics Advancements Could Aid Breast Cancer Prevention By Tom LydonAugust 4, 2021
Disruptive Technology Content Hub Unpacking the Potential of the Synthetic Biology Space By Tom LydonJuly 21, 2021
Disruptive Technology Content Hub How Healthcare ETFs Can Get Their Swagger Back By Tom LydonJuly 14, 2021
Disruptive Technology Content Hub The ARKG ETF and the Intersection of All Things Tech By Tom LydonJuly 13, 2021
Disruptive Technology Content Hub Play the New Era of Gene Editing with the ARKG ETF By Tom LydonJuly 2, 2021
Disruptive Technology Content Hub New Gene Editing Trial Results Bump the ARKG ETF By Tom LydonJune 29, 2021
Disruptive Technology Content Hub Biogen Alzheimer’s Approval Could Signal FDA’s Flexibility By Tom LydonJune 15, 2021
Disruptive Technology Content Hub Pandemic Opening the Door for Widespread Genetic Testing By Tom LydonJune 2, 2021
Disruptive Technology Content Hub A Base Hit: How Base Editing Is Changing Genomics By Tom LydonMay 26, 2021
Disruptive Technology Content Hub How Genomics Is Improving Cancer Screening, Investing By Tom LydonMay 18, 2021
